Introduction {#s1}
============

Since the 5th World Symposium on Pulmonary Hypertension (WSPH) in 2013, major progress has occurred in the understanding and management of chronic thromboembolic pulmonary hypertension (CTEPH). First, the link between CTEPH and acute pulmonary embolism, and some of the challenges associated with making the connection, will be reviewed. Key diagnostic steps in establishing early and accurate diagnosis will be emphasised. Each component of the current CTEPH treatment approach will be overviewed. Finally, an updated treatment algorithm is proposed taking into account the advances since 2013.

CTEPH and pulmonary embolism {#s2}
============================

CTEPH is classified within group 4 PH \[[@C1]\], and is characterised pathologically by organised thromboembolic material and by altered vascular remodelling initiated or potentiated by a combination of defective angiogenesis, impaired fibrinolysis and endothelial dysfunction \[[@C2]--[@C4]\]. These changes lead to PH and ultimately right ventricular failure \[[@C5], [@C6]\]. The precise pathogenesis of CTEPH remains unclear, but appears to be incited by acute pulmonary embolism \[[@C7]\].

However, classic risk factors for venous thromboembolism do not appear to increase the risk of CTEPH \[[@C8]\] and there are clear geographic differences in CTEPH epidemiology. An international CTEPH registry (Europe and Canada) indicated that 75% of patients with CTEPH had a documented antecedent history of acute pulmonary embolism \[[@C9]\], while in Japan, the rates of acute pulmonary embolism preceding CTEPH range from only 15% to 33% \[[@C10], [@C11]\]. There is an 80% female preponderance of CTEPH in Japan; these statistics differ significantly from the USA and Europe \[[@C9]\]. A number of abnormal autoimmune, inflammatory and thrombophilia markers have been found in CTEPH patients \[[@C2]\]; it is feasible that variability in this underlying pathological milieu contributes to the variability in the worldwide CTEPH epidemiology. Furthermore, variable gene expression has been demonstrated in pulmonary artery endothelial cells from patients with CTEPH compared with normal controls \[[@C12]\].

In published prospective studies with the diagnosis confirmed by right heart catheterisation (RHC) the incidence of CTEPH after symptomatic acute pulmonary embolism is reported to range from 0.4% to 6.2% \[[@C13]--[@C25]\], giving a pooled incidence of 3.4% (95% CI 2.1−4.4%) \[[@C7]\]. Since that analysis, a new report from Switzerland screened 508 patients after acute pulmonary embolism over 2 years and found a cumulative incidence of CTEPH confirmed with RHC of just 0.79% \[[@C26]\].

Determining the precise CTEPH incidence is complex. CTEPH is likely both underdiagnosed and the incidence of CTEPH after acute pulmonary embolism prone to overestimation, making the actual incidence difficult to quantify. Non-specific symptoms, variable rates of antecedent acute pulmonary embolism and the expertise required to read computed tomography pulmonary angiography (CTPA) contribute to underdiagnosis \[[@C27], [@C28]\]. Underdiagnosis is further compounded by the infrequent use of lung ventilation/perfusion scintigraphy (*V*/*Q* scan) despite guideline recommendations \[[@C29], [@C30]\]. Approximately 30 000 acute pulmonary embolism cases are diagnosed annually in France, with the CTEPH incidence estimated at 3.4% \[[@C31]\]. G[uérin]{.smallcaps} *et al.* \[[@C22]\] suggested a CTEPH incidence of 4.8%. Neither of these estimates is consistent with the current frequency of newly diagnosed CTEPH. A limitation of the numerous CTEPH incidence reports after acute pulmonary embolism may be attributed to an unrecognised amalgam of incident and prevalent cases \[[@C22]\].

In terms of reducing the risk of CTEPH following acute pulmonary embolism, no prospective randomised acute pulmonary embolism trials have examined systemic or catheter-based thrombolysis or clot extraction with RHC as an outcome measure in patients with persistent symptoms. Claims have been made that the incidence of CTEPH in patients receiving thrombolytic therapy is reduced, but end-points such as an echocardiogram-derived systolic pulmonary arterial pressure (sPAP) of 40 mmHg do not define PH or CTEPH \[[@C32]\]. Systemic thrombolysis failed to reduce the risk of CTEPH in intermediate/high-risk (submassive) pulmonary embolism patients in the 3-year follow-up of the PEITHO trial (average sPAP at follow-up was around 31 mmHg in each group) \[[@C33]\]. To date, there is no proof that aggressive treatment of acute pulmonary embolism can prevent CTEPH.

Chronic thromboembolic disease {#s3}
==============================

Chronic thromboembolic disease (CTED) is characterised by similar symptoms and perfusion defects, but without PH at rest. Currently a new threshold for PH (mean PAP (mPAP) \>20 mmHg) and pre-capillary PH (combination of mPAP \>20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg and pulmonary vascular resistance (PVR) ≥3 Wood Units) has been proposed by the 6th WSPH Task Force on PH diagnosis and classification \[[@C1]\]. While there is good evidence to suggest these new thresholds, the consequences for CTEPH and CTED, respectively, are not yet established. In the future, however, these new thresholds might also be applied to group 4 PH. Exercise limitation in CTED has been attributed either to exercise-induced PH, with an increased slope of the pulmonary arterial pressure--flow relationship, or to dead-space ventilation, with increased ventilatory equivalents for carbon dioxide \[[@C34], [@C35]\]. Both new and worsened dyspnoea and persistent perfusion defects are often encountered after acute pulmonary embolism, in, respectively, 30% and 30--50% of patients, which makes the recognition of CTED challenging \[[@C18], [@C36], [@C37]\]. Cardiopulmonary exercise tests and echocardiographic evaluations are recommended to exclude patients in whom symptoms are related to lung disease, left heart disease, obesity or deconditioning. A tentative, comprehensive definition of CTED is proposed in [table 1](#TB1){ref-type="table"}. Selected patients with CTED may benefit from pulmonary endarterectomy (PEA) as shown in a series of 42 patients out of 1019 who underwent surgery in the UK reference centre \[[@C38]\]. Post-operative improvement in symptoms, functional class and quality of life were reported. However, while there was no in-hospital mortality, major complications occurred in 40% of the cohort (small subdural haematomas, tracheostomy). Although endarterectomy is aimed to prevent subsequent disease, the natural history of CTED is unknown and there is no evidence that CTED evolves to CTEPH. At present, patients with CTED represent a group in need of both symptom relief and better understanding of their disorder. CTEPH treatment guidelines should not be applied to CTED.

###### 

Chronic thromboembolic disease (CTED) compared with chronic thromboembolic pulmonary hypertension (CTEPH)

  **Diagnostic criteria**                     **CTEPH**                                       **CTED**
  ------------------------------- --------------------------------- -------------------------------------------------------------
  **Symptoms**                            Exercise dyspnoea                               Exercise dyspnoea
  **PH**                                  *Present at rest*                               *Absent at rest*
  **RHC at exercise**                            * *                           *mPAP/CO slope \>3 mmHg·L^−1^·min^−1^*
  ***V*/*Q* scan**                 Any mismatched perfusion defect                 Any mismatched perfusion defect
  **Angiography (CTPA or DSA)**       Typical findings of CTEPH                       Typical findings of CTEPH
  **CPET**                                       * *                     *Excluding ventilatory limitation, deconditioning*
  **TTE**                                        * *                 *Excluding left ventricular myocardial or valvular disease*
  **Anticoagulation**                     At least 3 months                               At least 3 months

RHC: right heart catheterisation; *V*/*Q*: ventilation/perfusion; CTPA: computed tomography pulmonary angiogram; DSA: digital subtraction angiogram; CPET: cardiopulmonary exercise test; TTE: transthoracic echocardiogram; mPAP: mean pulmonary arterial pressure; CO: cardiac output.

Diagnosis of CTEPH {#s4}
==================

A normal *V*/*Q* scan effectively excludes CTEPH with a sensitivity of 90--100% and a specificity of 94--100% \[[@C39], [@C40]\]. In a study of confirmed cases of CTEPH, *V*/*Q* scan was found to be superior to CTPA with a sensitivity of 97.4% *versus* 51% \[[@C39]\]. This difference has narrowed as CT technology and interpretation have advanced. Indeed, a more recent study has shown that both *V*/*Q* scan and CTPA are accurate methods for the detection of CTEPH with excellent diagnostic efficacy (100% sensitivity, 93.7% specificity and 96.5% accuracy for *V*/*Q* scan; 96.1% sensitivity, 95.2% specificity and 95.6% accuracy for CTPA) \[[@C40]\]. However encouraging, *V*/*Q* scan remains the preferred initial imaging test for CTEPH screening \[[@C5], [@C29]\]. Recent retrospective studies have also assessed the diagnostic accuracy of three-dimensional dynamic contrast-enhanced lung perfusion magnetic resonance imaging (MRI) against planar *V*/*Q* scan or SPECT (single photon emission CT) scan as a screening tool for CTEPH \[[@C41], [@C42]\]. These studies demonstrated that dynamic contrast-enhanced lung perfusion MRI has a similar sensitivity (97%) for diagnosing CTEPH when compared with planar *V*/*Q* scan and a higher sensitivity (100% *versus* 97%) when compared with SPECT scan. Prospective studies examining the value of lung perfusion MRI and SPECT scan as a screening test for CTEPH are required to address the clinical utility (including their costs) and diagnostic performance of these modalities.

Digital subtraction angiography (DSA) had been considered the gold standard for characterising vessel morphology in CTEPH, but is being challenged by advances in non-invasive modalities. CTPA is currently widely used for assessment of operability. CTPA in more recent reports has a high sensitivity and specificity in detecting chronic thromboembolic lesions at the main/lobar (89--100% and 95--100%, respectively) and segmental (84--100% and 92--99%, respectively) levels \[[@C43]--[@C45]\]. CTPA can also be valuable by revealing bronchial artery collaterals, which can correlate with more central disease \[[@C46]\], and by evaluating the lung parenchyma and mediastinum. Advanced CT technologies, including dual-energy CT (DECT), ECG-gated area detector CT (ADCT), cone-beam CT (CBCT) and contrast-enhanced magnetic resonance pulmonary angiography, are emerging as valuable modalities for detailing the pulmonary vasculature. With advances with distal endarterectomy and the advent of balloon pulmonary angioplasty (BPA), and general focus on more distal vascular assessment, conventional DSA may not always be suitable for providing fine details. More selective segmental angiography, CBCT and ADCT may be better for pre-BPA planning by providing greater resolution than conventional DSA, particularly in the more distal vessels \[[@C47]\]. These imaging techniques are not widely available and require expertise.

Pulmonary endarterectomy {#s5}
========================

PEA should be offered to all eligible patients with CTEPH. The international registry of incident cases of CTEPH reported 3-year survival of 90% in those operated and 70% in those not having surgery \[[@C48]\]. Long-term follow-up of a large cohort reported 10-year survival of 72% (average age 58 years) \[[@C49]\]. Death was attributed to unrelated causes in 49% of patients; residual PH with PVR ≥425 dyn·s·cm^−5^ correlated with worse survival \[[@C49]\]. Strict objective definitions of operability remain elusive, but certain features are more likely to predict a good surgical outcome ([table 2](#TB2){ref-type="table"}). While select patients may be technically operable, they may not benefit from endarterectomy due to significant comorbidities; the best treatment for such cases remains uncertain. The traditional routine of inserting an inferior vena cava filter (IVC) device prior to endarterectomy has not been formally studied and has been abandoned at the leading surgical centres. In the international registry, IVC filter prior to surgery did not influence long-term survival \[[@C48]\].

###### 

Favourable risk--benefit assessment for pulmonary endarterectomy

  **Characteristics**                                      **Lower risk with predictable good long-term outcome**                                                  **Higher risk with less predictable long-term outcome (not contraindications)**
  --------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  **History**                                                                History of DVT/PE                                                                                                   No history of DVT/PE
  **Examination**                                                     No signs of right heart failure                                                                                        Signs of right heart failure
  **Comorbidity**                                                                   None                                                                                          Significant concomitant lung or left heart disease
  **Functional limitation**                                              Functional class II or III                                                                                              Functional class IV
  **Imaging**                                                      Clear disease concordant on all images                                                                                Inconsistency on imaging modalities
  **Type of disease**                                                   Bilateral lower lobe disease                                                                                    No disease appreciable in lower lobes
  **Haemodynamics**            PVR \<1000 dyn·s·cm^−5^, in proportion to site and number of obstructions on imaging; higher PA pulse pressure   PVR \>1200 dyn·s·cm^−5^, out of proportion to site and number of obstructions on imaging; higher PA diastolic pressure

DVT: deep vein thrombosis; PE: pulmonary embolism; PVR: pulmonary vascular resistance; PA: pulmonary artery.

The most important surgical advance has been in redefining the distal limits of endarterectomy \[[@C50], [@C51]\]. In expert centres, surgery can be performed successfully in patients with distal chronic thromboembolism \[[@C51]\]. The advances in diagnostics and growing surgical experience have contributed to this success. As a result, the previously published intra-operative classification \[[@C52]\] has been refined to better reflect the current surgical approach and level of revascularisation ([table 3](#TB3){ref-type="table"}) \[[@C50]\]. This also means not all surgical centres will view operability in the same manner \[[@C53]\]. A three-step stratified definition of expert surgical centre has been proposed which factors the following important goals: surgical mortality (\<5%), surgical volume (more than 50 PEAs per year) and ability to perform segmental endarterectomy \[[@C53]\]. Furthermore, in this era of a comprehensive approach to CTEPH, an expert centre should be capable of evaluating and offering any/all established treatment modalities according to individual need.

###### 

University of California San Diego chronic thromboembolism (CTE) surgical classification

  **Surgical levels**   **Location of CTE**
  --------------------- ------------------------------------------------------------------------------------------
  **Level 0**           No evidence of thromboembolic disease in either lung
  **Level I**           CTE starting in the main pulmonary arteries
   (Level IC)            (Complete occlusion of one main pulmonary artery with CTE)
  **Level II**          CTE starting at the level of lobar arteries or in the main descending pulmonary arteries
  **Level III**         CTE starting at the level of the segmental arteries
  **Level IV**          CTE starting at the level of the subsegmental arteries

Information from \[50\].

The place of PH-targeted medical therapy and BPA relative to surgery is dependent on the anatomical distribution of disease and is not fully defined. Combining endarterectomy with BPA either as a hybrid or stepwise approach is being evaluated at select expert programmes \[[@C54]\]. In the CHEST-1 study, riociguat was beneficial for patients with residual PH after endarterectomy \[[@C55]\]. A trial is needed to clarify if PH-targeted medical therapy prior to endarterectomy in operable patients confers harm or benefit ([ClinicalTrials.gov](https://clinicaltrials.gov/) identifier NCT0327357).

Balloon pulmonary angioplasty {#s6}
=============================

BPA has evolved into an important component of the CTEPH treatment algorithm since the 2012 reports from Japan \[[@C56]--[@C58]\]. BPA has been reported to improve haemodynamics, symptoms, exercise capacity and right ventricular function, with significantly lower rates of major complications than compared with the report from 2001 \[[@C59]--[@C62]\]. In retrospective analyses, the benefits of BPA also appear to be maintained in the medium term \[[@C10], [@C63]\]. Subsequent publications from Europe report similar results \[[@C64]--[@C66]\]. The recent BPA series from Germany is unique as these centres started BPA alongside a well-established PEA programme \[[@C67]\]. Although their complication rates were similar to those from Japan, the magnitude of efficacy (*e.g.* PVR reduction) was less in comparison with the reports from Japan. The potential explanations offered included the possibility of differences in operability threshold and the variability in the types of patients treated with BPA between centres.

Although these results of BPA are encouraging, the reports are from expert centres and may not be generalisable. Even with the technical refinements, there remains a steep learning curve in order to safely, effectively and consistently perform BPA \[[@C68]\]. A successful BPA requires extensive training and case experience. BPA should be reserved for expert centres, where it should be considered for symptomatic CTEPH patients ineligible for PEA due to distal chronic thromboembolism or persistent/recurrent PH after surgery. The role of BPA for those with technically operable disease, but who are unsuitable for surgery due to subjective determination or patient refusal, has not been established.

BPA patient selection at an expert centre starts with a multidisciplinary review of all available and pertinent data. Anatomical and functional assessment of pulmonary arteries and lung perfusion are critical to identify the target vessels \[[@C69]\]. A selective pulmonary angiogram of the target vessels will show more details and serves as confirmation prior to intervention during BPA. A selective angiogram may not capture all the distal lesions potentially amenable to BPA, necessitating multiple complementary imaging modalities such as intravascular imaging and pressure gradient analysis to aid in lesion assessment and balloon sizing \[[@C70]\].

BPA complications should be defined and uniformly reported. Unlike reperfusion lung injury after PEA which can be delayed for days before onset \[[@C71]\], the injury associated with BPA appears to be more vascular injury related to the intervention than the capillary leak syndrome described post-PEA \[[@C72]\]. [Table 4](#TB4){ref-type="table"} is proposed as a guide for BPA centres for classification of complications. Injury caused by wire perforation or interruption of the diseased vessel is the most common \[[@C69]\]. Lung injury by wire perforation or balloon overdilatation in the setting of severe PH risks potentially fatal massive infiltration and/or haemorrhage which may require mechanical ventilation or extracorporeal support. Classic reperfusion lung injury is rare with BPA. Published low BPA complications reflect limited experience confined to experienced BPA centres. In experienced hands, BPA has emerged as a promising and established treatment for inoperable CTEPH.

###### 

Balloon pulmonary angioplasty complications

  ------------------------------------------------------------------------------------------
  **During the procedure**
   Vascular injury^\#^ with/without haemoptysis
    Wire perforation
    Balloon overdilatation
    High-pressure contrast injection
   Vascular dissection
   Allergic reaction to contrast
   Adverse reaction to conscious sedation/local anaesthesia
  **After the procedure**
   Lung injury^¶^ (radiographic opacity with/without haemoptysis, with/without hypoxaemia)
   Renal dysfunction
   Access site problems
  ------------------------------------------------------------------------------------------

^\#^: signs of vascular injury: extravasation of contrast, hypoxaemia, cough, tachycardia, increased pulmonary arterial pressure; ^¶^: causes of lung injury: vascular injury much greater than reperfusion lung injury.

PH-targeted medical therapy {#s7}
===========================

While PEA remains the treatment of choice for most patients with CTEPH, around 40% of the patients in the international CTEPH registry were considered inoperable due to concern for inaccessible vascular obstruction, PAP out of proportion to morphological lesions and significant prohibitive comorbidities \[[@C9]\]. A large number of small studies and three large randomised controlled trials ([table 5](#TB5){ref-type="table"}) have demonstrated varying improvements with targeted medical therapy in technically inoperable patients \[[@C55], [@C73], [@C74]\]. However, data are lacking for patients with medical contraindications or those refusing surgery. Riociguat is the currently approved medical therapy in many countries for inoperable CTEPH based on the CHEST trials \[[@C55], [@C75]\]. Recently, the MERIT-1 trial of macitentan in the treatment of inoperable CTEPH showed improvements of the primary end-point (PVR (p=0.041)) and of other end-points (*e.g.* 6-min walk distance (p=0.033) and N-terminal pro-brain natriuretic peptide (p=0.040)) \[[@C74]\]. This last study provided the first evidence on combination drug therapy in CTEPH. 61% of the included patients were already treated with phosphodiesterase type 5 inhibitors and/or oral/inhaled prostanoids at inclusion, and addition of macitentan showed similar efficacy compared with the drug-naive patients. Accordingly, macitentan is being considered for potential CTEPH registration. Event-driven morbidity/mortality studies have not been performed in CTEPH.

###### 

Pulmonary hypertension-targeted medical therapy randomised controlled trials in chronic thromboembolic pulmonary hypertension

  **Trial \[ref.\]**    **Study drug**   **Duration weeks**   **Subjects n**   **NYHA FC**   **6MWD m**    **6MWD effect m**     **PVR baseline dyn·s·cm^−5^**   **PVR effect %**
  -------------------- ---------------- -------------------- ---------------- ------------- ------------ ---------------------- ------------------------------- ------------------
  **BENEFIT \[73\]**       Bosentan              16                157           II--IV        342±84     +2^[ns]{.smallcaps}^       783 (95% CI 703--861)             −24
  **CHEST-1 \[55\]**      Riociguat              16                261           II--IV        347±80             +46                       787±422                    −31
  **MERIT-1 \[74\]**      Macitentan        16 (24^\#^)             80           II--IV        352±81             +34                       957±435                    −16

Data are presented as n or mean±[sd]{.smallcaps}, unless otherwise stated. NYHA FC: New York Heart Association Functional Class; 6MWD: 6-min walk distance; PVR: pulmonary vascular resistance; [ns]{.smallcaps}: non-significant. All three trials had an adjudication process for operability. ^\#^: 6MWD measured at 24 weeks.

Patients with persistent/residual post-operative PH were also included in BENEFIT and CHEST-1, representing around 30% of the study population \[[@C55], [@C73]\]. Both studies included patients with mPAP ≥25 mmHg and PVR ≥300 dyn·s·cm^−5^ at \>6 months after endarterectomy. This can be put in perspective with real-life data from the large UK national cohort, in which 3--6 months after PEA: 1) 51% of the patients had mPAP ≥25 mmHg, 2) mPAP ≥30 mmHg predicted initiation of PH-targeted medical therapy, and 3) mPAP ≥38 mmHg and PVR ≥425 dyn·s·cm^−5^ correlated with worse long-term survival \[[@C49]\].

Using medical therapy as a "bridge to PEA" is more controversial, and is felt to delay timely surgical referral and, therefore, definitive treatment. In the international registry and in a University of California San Diego cohort, 28% and up to 37%, respectively, of the patients were on some form of PH-targeted drug(s) at the time of surgical referral \[[@C9], [@C76]\]. In both cohorts, the delay between diagnosis and surgery was doubled in the pre-treated patients, without demonstrable clinical benefit. In the international registry, pre-treatment even independently predicted worse outcome (hazard ratio 2.62; p=0.0072) \[[@C48]\]. Key limitations of these reports are with inherent referral bias and the possibility of medical therapy potentially stabilising otherwise deteriorating cases (unknown and not tested). In order to provide the missing evidence, a phase 2 study will soon commence to include CTEPH patients with high PVR for pre-operative treatment with riociguat *versus* placebo ([ClinicalTrials.gov](https://clinicaltrials.gov/) identifier NCT0327357). Using medical therapy as a "bridge to BPA", although not studied, has become common practice and in keeping with the indication for riociguat for technically inoperable disease. A study is currently ongoing which compares riociguat *versus* BPA for technically inoperable CTEPH, followed by an opportunity to crossover after 6 months ([ClinicalTrials.gov](https://clinicaltrials.gov/) identifier NCT02634203).

CTEPH treatment algorithm {#s8}
=========================

The newly proposed CTEPH treatment algorithm is provided in [figure 1](#F1){ref-type="fig"} and starts with lifelong anticoagulation. Antiplatelet therapy is not an alternative to anticoagulation in patients with CTEPH. Data differentiating the best form of anticoagulation therapy is lacking in CTEPH. Traditional anticoagulation has been with oral vitamin K antagonists. Whether the newer oral anticoagulants or chronic injectable anticoagulants are adequate in CTEPH is unknown. The algorithm emphasises the need for a multidisciplinary assessment, including a surgeon experienced with PEA, PH specialist, BPA interventionist and CTEPH-trained radiologist. A PH referral centre was previously defined and recommended as a minimum volume of 50 pulmonary arterial hypertension or CTEPH patients managed per year \[[@C77]\]. However, given the highly specialised nature of CTEPH treatment, additional factors should be considered when gauging clinical expertise.

![Chronic thromboembolic pulmonary hypertension (CTEPH): revised treatment algorithm. BPA: balloon pulmonary angioplasty. ^\#^: multidisciplinary: pulmonary endarterectomy surgeon, PH expert, BPA interventionist and radiologist; ^¶^: treatment assessment may differ depending on the level of expertise; ^+^: BPA without medical therapy can be considered in selected cases.](ERJ-01915-2018.01){#F1}

In the CHEST-1 trial, central adjudication exemption and local operability assessment were allowed provided a participating centre performed more than 20 PEA operations per year \[[@C78]\]. However, the majority of the operability adjudication occurred with the central committee whose members each performed well in excess of 50 operations per year. In addition, the central adjudication committee had double the rate of operability determination than the local adjudication committee (15% operable *versus* 7% operable, respectively). From the international CTEPH registry, a trend with the best in-hospital and 1-year post-operative mortality was observed from centres performing higher volumes of PEA, with the best results observed from centres performing more than 50 operations per year \[[@C79]\]. This observation likely does not take into account the relative differences in case complexity, with potentially more challenging cases referred to higher-volume programmes. Additional emphasis on the importance of surgical centre experience was reported in the UK national registry of patients undergoing PEA \[[@C49]\]. In this report, significantly lower in-hospital mortality was observed in the second group of consecutive 500 operated cases compared with the initial group of 500 operated cases. In addition, the ability for high-volume centres to perform more distal endarterectomy necessitates stratification of surgical centre expertise \[[@C53]\]. A similar observation applies to BPA success; the safety and efficacy reports of the refined BPA techniques from Japan are from centres performing the highest volume of procedures (typically more than 100 per year) \[[@C58], [@C59]\]. In summary, an expert CTEPH centre should be able to assess and deliver all established treatment modalities with outcomes similar to or exceeding those published.

Patients with operable CTEPH should receive PEA as the treatment of choice. For those deemed inoperable, the best level of evidence supports initiating medical therapy and consideration of BPA. Patients with persistent/recurrent symptomatic PH following PEA should receive medical therapy and be considered for BPA or re-do endarterectomy in cases of significant re-occlusion \[[@C80]\]. Lastly, given the subjectivity of operability assessment, it is possible for a patient initially deemed to be inoperable to receive PEA with or without treatments for inoperable CTEPH. The new algorithm therefore allows for fluidity between these treatment modalities as information and expertise is gained.

Conclusions {#s9}
===========

PEA remains the treatment of choice for patients with operable CTEPH. Two additional recognised treatments are now available (*i.e.* targeted medical therapy and BPA). A multimodal, individualised approach to treatment at expert centres integrating surgical, interventional, imaging and medical PH expertise with the development of clear outcomes analyses is mandatory going forward.
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